NCT07460765 2026-03-10
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Vanderbilt-Ingram Cancer Center
Phase 1 Not yet recruiting
Vanderbilt-Ingram Cancer Center
Eli Lilly and Company
NRG Oncology
Royal Marsden NHS Foundation Trust
VLP Therapeutics
H. Lee Moffitt Cancer Center and Research Institute